🟢 SLDB Surges 5.1% After H.C. Wainwright Hikes Price Target and Addition to S&P Biotechnology Index

Solid Biosciences (SLDB) is trading 5.1% up today at $8.72, driven by recent positive company-specific developments.

• H.C. Wainwright raised its price target for SLDB from $20 to $25 and reiterated a Buy rating on June 21, 2026, citing encouraging SGT-212 Friedreich's ataxia data.
• The company was also added to the S&P Biotechnology Select Industry Index, effective June 22, 2026.
• This performance stands out against a broadly weaker market backdrop, indicating strong positive investor reaction to these catalysts.